Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anxiety
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anxiety
    Melatonin Reduces Emergence Delirium Post-Anaesthesia in Children - (DGNews)
    Desvenlafaxine Reduces Anxiety Associated With Major Depressive Disorder: Presented at WCBP - (DGDispatch)
    Extended-Release Quetiapine Effective for Older Adults With Generalised Anxiety Disorder: Presented at WCBP - (DGDispatch)
    TopAbstracts in Anxiety 06/24/2009 - (DGNews)
    TopAbstracts in Anxiety 06/10/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Anxiety

    Webcasts/CME archive

     Recent cases - Anxiety
      Diagnosing and Managing Post-Traumatic Stress Disorder
      Chronic Dizziness Presenting in a Patient with Panic Disorder: Response to Imipramine
      Aripiprazole Augmentation in Poor Insight Obsessive-Compulsive Disorder: A Case Report
      Recurrence of Suicidal Ideation Due to Treatment with Antidepressants in Anxiety Disorder: A Case Report
      Persistent Tardive Rebound Panic Disorder, Rebound Anxiety and Insomnia Following Paroxetine Withdrawal: a Review of Rebound-Withdrawal Phenomena

      Cases archive
        




      my personal edition > anxiety > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Venlafaxine and Paroxetine Provide Comparable Quality of Life Improvements in Panic Disorder, but High-Dose Venlafaxine May Provide Slight Advantage: Presented at ADAA

      By Bonnie Darves

      SEATTLE, WA -- March 21, 2005 -- Patients with panic disorder who take either venlafaxine or paroxetine appear to gain significant improvement in quality of life and overall functioning, but venlafaxine in lower doses does not appear to provide as much benefit as a higher dose of the drug.

      According to a new study presented here on March 19th at the Anxiety Disorders Association of America 25th Annual Conference, the drugs are similarly efficacious in boosting most quality of life (QOL) domains, said lead author Rezaul Khandker, PhD, director of health outcomes, Wyeth, Collegeville, Pennsylvania, United States.

      "There was virtually no difference between the drugs in quality of life and functional ability, but we did not see much improvement in the school performance and course work domain for either drug," he said. The short treatment duration, 12 weeks, may have "made it difficult for patients to detect improvements in that domain," Dr. Khandker added.

      The randomized, double-blind, fixed-dose study included 621 patients with diagnosed panic disorder who received either 75 or 225 mg of venlafaxine, 40 mg of paroxetine or placebo for up to 12 weeks.

      Baseline scores on the Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were comparable across all domains for the active-treatment and placebo groups (2.5 and 3.5). This -- relatively new -- rating scale includes 10 subscales that measure such domains as subjective feelings of well-being, leisure time, social relationships and satisfaction with medication. Patient-reported functioning was assessed using the Sheehan Disability Scale.

      At the study's completion, scores in the Q-LES-Q domains of physical health and activities, overall life satisfaction, and subjective feelings of well-being improved by 1.25 points or more in all treatment groups, but showed negligible improvement in the placebo patients.

      Dr. Khandker noted that the improvements in most domains were less visible in the 75-mg venlafaxine group than in the other two active treatment arms. In the satisfaction with medication domain, for example, patients on the 225 mg venlafaxine dose registered a 1.7-point change versus 1.7 on the 75 mg dose.


      [Presentation title: Patient-reported QOL and Functionality in Panic Disorder: Venlafaxine, Paroxetine and Placebo. Poster 155]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send